Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
The Pharma Data
APRIL 7, 2021
months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. months from 1.7 0.54; p<0.0001). Trodelvy also extended median overall survival (OS) to 11.8 months vs. 6.9
52 
Let's personalize your content